Academic literature on the topic '70-ia'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '70-ia.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "70-ia"
1
Frohmaier, C., M. Sullivan, P. E. Nugent, M. Smith, G. Dimitriadis, J. S. Bloom, S. B. Cenko, et al. "The volumetric rate of normal type Ia supernovae in the local Universe discovered by the Palomar Transient Factory." Monthly Notices of the Royal Astronomical Society 486, no. 2 (March 19, 2019): 2308–20. http://dx.doi.org/10.1093/mnras/stz807.
Full textAbstract:
Abstract We present the volumetric rate of normal type Ia supernovae (SNe Ia) discovered by the Palomar Transient Factory (PTF). Using strict data-quality cuts, and considering only periods when the PTF maintained a regular cadence, PTF discovered 90 SNe Ia at z ≤ 0.09 in a well-controlled sample over three years of operation (2010–2012). We use this to calculate the volumetric rate of SN Ia events by comparing this sample to simulations of hundreds of millions of SN Ia light curves produced in statistically representative realizations of the PTF survey. This quantifies the recovery efficiency of each PTF SN Ia event, and thus the relative weighting of each event. From this, the volumetric SN Ia rate was found to be $r_\mathrm{ v}=2.43\pm 0.29\, \text{(stat)}_{-0.19}^{+0.33}\text{(sys)}\times 10^{-5}\, \rm{SNe\,yr}^{-1}\, \text{Mpc}^{-3}\, h_{70}^{3}$. This represents the most precise local measurement of the SN Ia rate. We fit a simple SN Ia delay-time distribution model, ∝ t−β, to our PTF rate measurement combined with a literature sample of rate measurements from surveys at higher redshifts. We find β ∼ 1, consistent with a progenitor channel governed by the gravitational inspiral of binary white dwarfs.
2
Seidel, Danila, Oliver Cornely, Dorothee Arenz, Jacques Meis, Jörg Vehreschild, Jon Salmanton-Garcia, Marouan Zarrouk, et al. "2268. Clinical Implications of Azole-Resistant vs. Azole-Susceptible Invasive Aspergillosis in Hematological Malignancy (CLARITY): A Multicenter Study." Open Forum Infectious Diseases 6, Supplement_2 (October 2019): S776. http://dx.doi.org/10.1093/ofid/ofz360.1946.
Full textAbstract:
Abstract Background In recent years, survival of patients with invasive aspergillosis (IA) has improved mainly due to availability of extended spectrum triazoles. These advances are jeopardized by the emergence of azole resistance in Aspergillus fumigatus, the most common causative pathogen of IA. Despite several studies suggesting high probability of azole treatment failure in patients with azole-resistant isolates, the clinical implications of azole-resistant IA compared with azole-susceptible IA remain unclear. Methods In patients with hematological malignancies, cases of proven or probable IA (EORTC/MSG 2008) caused by A. fumigatus are registered. Retrospective data are documented, comprising demographics, diagnosis, treatment, response and outcome. Participating sites provided susceptibility results or isolates. Provided isolates were analyzed in a central laboratory. Results Since January 2018, 51 sites in 15 countries worldwide enrolled 154 cases diagnosed with IA between 2010 and 2019, of which 23 (14.9%) had azole-resistant IA. Of 44 cases, the respective clinical fungal isolate was analyzed in the central laboratory. A mixed fungal infection was reported for 34 patients (22.1%), 1 (2.9%) in the azole-resistant group; most were related to non-fumigatus Aspergillus species (n = 12, 35.3%) and non-Aspergillus molds (n = 10, 29.4). Most patients were male (n = 98, 63.6%); 19 (82.6%) in the azole-resistant group, 79 (60.3%) in the azole-susceptible group. Age was documented in categories instead of the exact age. Median age group was 50–69 years in both groups (ranging from 7–11 to 70–89 years for azole-resistant cases, 1–12 months to 70–89 years for azole-susceptible cases). Underlying disease and survival are shown in the table. Conclusion A worldwide network of investigators contributes to the CLARITY registry study. Completion of recruitment and subsequent data analysis are planned for 2019. Further sites may be added if azole-resistant cases are encountered. Disclosures All authors: No reported disclosures.
3
Craig, D. M., J. H. Galla, D. N. Bonduris, and R. G. Luke. "Importance of the kidney in the correction of chloride-depletion alkalosis in the rat." American Journal of Physiology-Renal Physiology 250, no. 1 (January 1, 1986): F54—F57. http://dx.doi.org/10.1152/ajprenal.1986.250.1.f54.
Full textAbstract:
Correction of chloride-depletion alkalosis (CDA) may involve renal as well as extrarenal mechanisms. To determine the relative contribution of these mechanisms in a rat model of CDA produced by peritoneal dialysis (PD), we studied six groups of anesthetized Sprague-Dawley rats after PD. Groups II-IV and IIa were subjected to functional bilateral nephrectomy, and groups I and Ia were sham-operated. Groups I, Ia, II, and IIa were infused with isotonic fluid containing 70 mM Cl- and 40 mM HCO3-; the infusate in group III was 140 mM Cl- and in group IV, 70 mM neutral PO4 was substituted for Cl-. Groups I and Ia were infused at 0.5 ml . h-1 X 100 g body wt-1 and groups II, IIa, III, and IV at 0.25 ml . h-1 X 100 g-1. After 3 h of infusion, early partial correction with reciprocal changes in plasma Cl (+6.1 +/- 1.9 mmHg) and total CO2 (-6.0 +/- 0.8 meq/liter) occurred (P less than 0.01) only in group I. Hypokalemia (3.1 +/- 0.1 meq/liter) also occurred only in group I. The responses of groups Ia and IIa studied at 5 h were similar to those of groups I and II. These data suggest that the kidney, and not extrarenal mechanisms, is primarily responsible for the correction of CDA during infusion of chloride.
4
Kieran, Emily A., Anne O’Sullivan, Jan Miletin, Anne R. Twomey, Susan J. Knowles, and Colm Patrick Finbarr O’Donnell. "2% chlorhexidine–70% isopropyl alcohol versus 10% povidone–iodine for insertion site cleaning before central line insertion in preterm infants: a randomised trial." Archives of Disease in Childhood - Fetal and Neonatal Edition 103, no. 2 (October 26, 2017): F101—F106. http://dx.doi.org/10.1136/archdischild-2016-312193.
Full textAbstract:
ObjectiveTo determine whether 2% chlorhexidine gluconate–70% isopropyl alcohol (CHX–IA) is superior to 10% aqueous povidone–iodine (PI) in preventing catheter-related blood stream infection (CR-BSI) when used to clean insertion sites before placing central venous catheters (CVCs) in preterm infants.DesignRandomised controlled trial.SettingTwo neonatal intensive care units (NICUs).PatientsInfants <31 weeks’ gestation who had a CVC inserted.InterventionsInsertion site was cleaned with CHX–IA or PI. Caregivers were not masked to group assignment.Main outcome measuresPrimary outcome was CR-BSI determined by one microbiologist who was masked to group assignment. Secondary outcomes included skin reactions to study solution and thyroid dysfunction.ResultsWe enrolled 304 infants (CHX–IA 148 vs PI 156) in whom 815 CVCs (CHX–IA 384 vs PI 431) were inserted and remained in situ for 3078 (CHX–IA 1465 vs PI 1613) days. We found no differences between the groups in the proportion of infants with CR-BSI (CHX–IA 7% vs PI 5%, p=0.631), the proportion of CVCs complicated by CR-BSI or the rate of CR-BSI per 1000 catheter days. Skin reaction rates were low (<1% CVC insertion episodes) and not different between the groups. More infants in the PI group had raised thyroid-stimulating hormone levels and were treated with thyroxine (CHX–IA 0% vs PI 5%, p=0.003).ConclusionsWe did not find a difference in the rate of CR-BSI between preterm infants treated with CHX–IA and PI, and more infants treated with PI had thyroid dysfunction. However, our study was not adequately powered to detect a difference in our primary outcome and a larger trial is required to confirm our findings.Trial registrationThis study was registered with the EU clinical trials register before the first patient was enrolled (Eudract 2011-002962-19). (https://www.clinicaltrialsregister.eu)
5
Kim, Kyungsuk, and Sanghun Lee. "Intradermal Acupuncture Along with Analgesics for Pain Control in Advanced Cancer Cases: A Pilot, Randomized, Patient-Assessor-Blinded, Controlled Trial." Integrative Cancer Therapies 17, no. 4 (July 16, 2018): 1137–43. http://dx.doi.org/10.1177/1534735418786797.
Full textAbstract:
Purpose: Ninety percent of patients with advanced cancer have moderate to severe pain, and up to 70% of patients with cancer pain do not receive adequate pain relief. This randomized controlled clinical trial was designed to determine the feasibility and evaluate the effects and safety of intradermal acupuncture (IA) in patients who were being administered analgesics for cancer pain. Methods: Advanced cancer patients experiencing pain were randomly assigned to IA or sham IA treatment for 3 weeks (15 patients for each group), wherein the CV12, bilateral ST25, LI4, LR3, PC06, and Ashi points were selected and stimulated. Follow-up evaluations were conducted 3 weeks after the end of treatments. The grade and dosage of analgesics for cancer pain, pain intensity, quality of life, and safety were assessed. Results: Twenty-seven patients (90%) completed 6-week trial, and no serious adverse events were associated with either IA or sham IA procedures except the transient side effect such as fatigue. Nine patients in the IA group (64.3%) and 5 in the sham IA group (38.5%) responded to the 3-week intervention. These patients were mostly in the nonopioid and the weak opioid levels of the World Health Organization analgesic ladder. Self-reported pain declined by −1.54 ± 1.45 and −1.15 ± 1.57 in the IA and sham IA groups, respectively, with improved quality of life reported. Conclusions: IA treatment appears feasible and safe for advanced cancer patients. It might reduce analgesic usage in the early World Health Organization analgesic ladder stage cancer patient, though it could not show significant outcome differences due to design limitation of sham IA.
6
Smith, Cardinale B., and Juan P. Wisnivesky. "Survival following segmentectomy and lobectomy for stage I non-small cell lung cancer." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 7064. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.7064.
Full textAbstract:
7064 Background: Although lobectomy is considered the standard surgical treatment forstage IA non–small cell lung cancer (NSCLC), limited resections are frequently performed for patients with poor lung function or high operative risk. Recent studies suggest that segmentectomy may be the superior limited resection procedure. The objective of this study was to compare survival among patients with stage IA (≤3cm) NSCLC undergoing lobectomy vs. segmentectomy. Methods: Using the Surveillance, Epidemiology and End Results registry we identified 15,180 cases of stage IA NSCLC that underwent lobectomy or segmentectomy. We used logistic regression to determine propensity scores for patients undergoing segmentectomy based on the patient’s preoperative characteristics. Overall and lung cancer-specific survival of patients treated with lobectomy versus segmentectomy was compared after adjusting, stratifying, or matching patients based on their propensity score. We also performed secondary analyses in subgroups of age (≤70 vs. >70 years) and tumor size ≤2 cm. Results: Overall, 1,200 (8%) patients underwent segmentectomy. Among the entire cohort, analyses adjusting for propensity scores did not demonstrate a difference in outcomes among patients treated with lobectomy versus segmentectomy, (adjusted hazard ratio [HR] for overall survival 1.11, 95% confidence interval [CI]: 0.94 – 1.30 and lung cancer-specific survival 1.11, 95% CI: 0.98 – 1.25). Similarly, secondary analyses showed no difference in overall (HR: 1.12, 95% CI: 0.90 – 1.40) and lung cancer-specific survival (HR: 1.04, 95% CI: 0.88 – 1.24) among patients with tumors ≤2 cm (T1a tumors). For patients ≤70 years of age, no difference in overall survival was observed (HR: 0.97, 95% CI: 0.73 – 1.28); however, a lung cancer-specific survival advantage of lobectomy was observed (HR: 1.19, 95% CI: 1.00 – 1.40). Finally, among those >70 years overall survival (HR: 1.03, 95% CI: 0.87 – 1.22) and lung cancer-specific survival (HR: 1.18, 95% CI: 0. 97 – 1.44) showed equivalence of the two surgical groups. Conclusions: Segmentectomy and lobectomy may lead to equivalent survival rates among patients with stage IA NSCLC. These study findings should be confirmed in prospective studies.
7
Alberto, Maria. "Queerbaiting and Fandom: Teasing Fans through Homoerotic Possibilities, Joseph Brennan (ed.) (2019)." Australasian Journal of Popular Culture 9, no. 2 (September 1, 2020): 280–82. http://dx.doi.org/10.1386/ajpc_00033_5.
Full text
8
Mordini, Nicola, Benedetto Bruno, Alessandro Busca, Roberto Sorasio, Mario Boccadoro, Eugenio Gallo, Andrea Gallamini, and Daniele Mattei. "Incidence of Invasive Aspergillosis in Allogeneic Stem Cell Transplantation Patients: An Italian Prospectic Multicenter Study." Blood 104, no. 11 (November 16, 2004): 5057. http://dx.doi.org/10.1182/blood.v104.11.5057.5057.
Full textAbstract:
Abstract Between January 2003 and June 2004, every consecutive patient admitted for HSCT in three institutions was monitored for circulating galactomannan (GM) with Platelia Aspergillus assay (Bio-Rad) twice weekly from admittance until day 100, and then once weekly until day 365. Following fever occurence or GM optical density index increase (+ve cut-off value was >0.7), screening with weekly chest HR CT scan was started. Diagnosis of IA was made according to the EORTC/MSG criteria. 74 patients were analyzed, and 100 entered by now in the present study. Clinical characteristics of the patients are reported in table 1. We observed 10 cases of probable IA and 2 cases of possible IA. IA occurred before day 40 in 3 patients (median, day 13 after HSCT), between day 40 and day 180 in 8 cases (median, day 109 after HSCT), and after day 180 in 1 patient. Among the probable IA group of patients, 7/10 had GVHD, 6/10 were given steroids, and 3/10 had fever. Two consecutive positive GM test results were observed in the sera of 6/10 patients, GM was detected in BAL only in 3/10 cases and 1 patient had GM detected only in a SNC fluid. Chest CT scan was diagnostic in 8/10 cases, and in another patient CNS RMN scan shown lesions consistent with IA. All patients were lymphopenic at the time of IA diagnosis with an absolute count <450 mm^3, and only 1 patient was neutropenic. 3/10 patients had CMV reactivation during the IA episode and 4/10 had CMV reactivation in the 100 days following IA diagnosis. Cumulative incidence of IA after day 60 was 8,1%, overall incidence of IA was 16.2%, and probability of developing IA reached 24% at 1year after HSCT. Cumulative incidence of IA in the RIC group was 12.3%.6/12 patients died of IA, with a median survival of 24 days (range 1–83). IA accounted for 37.5% (6/16) of all deaths and for 55% of non-relapse deaths. 1-year survival in the IA group was 22% and 80% in non-IA group. Bimodal incidence distribution of IA after HSCT was confirmed, 25% of IA cases were diagnosed early (< day 40) after HSCT, 67% were diagnosed between day 40 and day 180, and an additional 8% developed after day 180. We confirm the role of GVHD and lymphopenia as important risk factors during the late post-transplantation periods. The relatively high incidence of IA could be a consequence of the increase of IA in recent years and of diagnostic improvement (GM+HR CT scan). We recommend the use of serial screening for GM after day 100 in patients lymphopenic or with GVHD. We need new diagnostic and therapeutic strategies for HSCT patients as IA accounts still for an unacceptable high portion of non-relapse deaths. Clinical characteristics of patients Patients 71 Disease Multiple myeloma 27 (38%) Myelodisplastic syndrome 8 (11.3%) Acute myeloid leukemia 9 (12.7%) Chronic myeloid leukemia 6 (8.5%) Hodgkin’s disease 5 (7%) Non Hodgkin’s lymphoma 8 (11.3%) Acute lymphoblastic leukemia 4 (5.6%) Chronic lymphatic leukemia 2 (2.8%) Aplastic anemia 1 (1.4%) Renal cell carcinoma 1 (1.4%) Mean age years (range) 48.8% (20–70) HSCT 74* HLA id RIC 52 (70.3%) MUD RIC 5 (6.8%) HLA id conventional 10 (13.5%) Syngeneic conventional 1 (1.3%) MUD conventional 5 (6.8%) MUD conventional UCB 1 (1.3%) Stem cell source PBSC 64 (86.5%) BM 9 (12.2%) UCB 1 (1.3%) Follow up days Median 214 Min 48 Max 595 GVHD Acute 53/74 (71%) Chronic 36/51 (70%) Chronic extensive 14/36 (39%) *Second transplant 3 patients
9
Thurlow, P. J., L. Kerrigan, R. A. Harris, and I. F. McKenzie. "Analysis of human bone marrow with monoclonal antibodies." Journal of Histochemistry & Cytochemistry 33, no. 12 (December 1985): 1183–89. http://dx.doi.org/10.1177/33.12.2415573.
Full textAbstract:
In order to study the antigenic phenotype of different hemopoietic cells, we used a series of monoclonal antibodies to investigate normal bone marrow in a standard immunofluorescence assay. The antibodies detected the following antigens: HLA-ABC, beta 2-microglobulin (beta 2m), HLA-DR (Ia), a lymphocyte subset and specific antigen (T and B) HuLy-m2, m3, T lymphocyte antigen (HuLy-m1), lymphocyte T200 antigen (HuLy-m4), a viral-associated antigen (HuLy-m5), and platelet-specific glycoproteins IIb-IIIa (HuPl-m1). The following results were obtained: (a) normoblasts were weakly HLA-ABC+, beta 2m+ and Ia-; all other lymphocyte and platelet antigens were not detected. (b) Myeloid cells at all stages of differentiation (promyelocytes, myelocytes, metamyelocytes, and neutrophils) were HLA-ABC+; beta 2m+; HuLy-m1-, m2-, m3+/- (20%), m4+, m5+/- (20%); HuPl-m1-; in addition, promyelocytes and myelocytes were Ia+ but neutrophils and metamyelocytes were Ia-. (c) Lymphocytes were HLA-ABC+, beta 2m+, Ia+/- (20-30%), HuLy-m1+/- (40-50%), m2+/- (60-70%), m3+, m4+, m5+; Pl-m1-. (d) Platelets and megakaryocytes were HLA-ABC+; beta 2m+; Ia-; HuLy-m1+-, m2-, m3-, m4-, m5-, HuPl-m1+, and the putative "megakaryocyte precursors" were HuPl-m1+, Ia-, HuLy-m1-. The different cell types in bone marrow could readily be distinguished, particularly cells of the myeloid series (Ia and HuLy-m4, m5), lymphocytes (Ia and HuLy-m1, m2, m3), and platelets and their precursor cells (HuPl-m1). This simple method of defining cellular phenotypes in bone marrow has demonstrated the practicality of using monoclonal antibodies to identify marrow cells and should be of diagnostic value.
10
Jiang, Hui Yu, Mei Hua Zhou, and Ding Pan. "Synthesis of Ultra-High Molecular Weight Polyacrylonitrile (UHMWPAN) by Aqueous Suspension Polymerization." Advanced Materials Research 1120-1121 (July 2015): 615–19. http://dx.doi.org/10.4028/www.scientific.net/amr.1120-1121.615.
Full textAbstract:
Acrylonitrile (AN) and itaconic acid (IA) were used to synthesize UHMWPAN by aqueous suspension method with 2,2’-azobisisobutyronitrile (AIBN) as the initiator and polyvinylalcohol (PVA) as the disperser at different temperatures (55°C~75°C) for different timings (1.0h~3.0h). The usage amounts of AN, IA, AIBN and PVA were also technical polymerization parameters used to obtain the optimal polymerization process. We found that the conversion and the viscosity average molecular weight both achieved the optimum levels when the conditions were as follows: the total monomer concentration (21wt%), the monomer ratio (AN: IA=98:2), the usage amount of the initiator (AIBN, 0.01wt%), the usage amount of the disperser (PVA, 0.1wt%), the polymerization temperature (70°C) and the polymerization time (2h).
Books on the topic "70-ia"
Book chapters on the topic "70-ia"
1
Junker, Abbo. "2. Kapitel. Brüssel Ia-Verordnung (EuGVVO)." In Internationales Zivilprozessrecht, 70–203. Verlag C.H.BECK oHG, 2020. http://dx.doi.org/10.17104/9783406761522-70.
Full textConference papers on the topic "70-ia"
1
Egosi, Nathiel G., Mark E. Raabe, Robert Weidner, and Gary A. Freel. "Plant Upgrade: Recovery of Non-Ferrous Metals From a Municipal RDF Facility." In 18th Annual North American Waste-to-Energy Conference. ASMEDC, 2010. http://dx.doi.org/10.1115/nawtec18-3510.
Full textAbstract:
The City of Ames, IA (City) processes 220 tons per day of municipal solid waste (MSW) at their Arnold O. Chantland Resource Recovery System (RRS). This facility is depicted in Figure 1. The objectives of this facility have both an economic and an environmental component: to reduce the amount of MSW that is otherwise disposed in their local landfill, thereby increasing the life of the landfill; and produce refuse-derived fuel (RDF) to reduce the amount of coal consumed at the City’s municipal electrical generating station. [Note: Approximately 70% of the MSW is converted into RDF, comprising 10 to 20% of the feedstock to the generating station.]
2
Roncaglioni, M. C., A. Falanga, A. P. Bolognese Dalessandro, B. Casali, and M. B. Donti. "ENZYMATIC AND IMMUNOLOGIC CHARACTERIZATION OF A CYSTEINE PROTEINASE PROCOAGULANT IN SEVERAL MURINE METASTASIZING TUMO." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643663.
Full textAbstract:
Involvement of the hemostatic systemin tumor metastasis growth has been repeatedly suggested and several tumor-associated procoagulants have been described. We have studied here the procoagulant activity (PCA) of tissue extracts from 4 murine metastasizing tumors: Lewis Lung Carcinoma (3LL), B16 melanoma (B16), JW sarcoma (JWS) and the M4 variant of the mFS6 fibrosarcoma (M4). The experiments were designed to identify cancer procoagulant (CP) a FVII independent FX activating cysteine proteinase or tissue factor (TF) in these tumors. Tissue extracts from 3LL, B16 and JWS initiated coagulation both in the presence and absence of FVII (FVII independent activity ranging from 70% to 86% of the total activity). The PCA of the same tumors was significantly decreased (p < 0.01) by cysteine proteinase inhibitors (1 mM iodoacetamide (IA) and 0.1 mM HgCl2 ) and the inhibitionby HgCl2 was reversed by -SH group activators (di-thiatreital, KCN, IiDTA). In addition these samples were able of directly activating pure bovineFX in a two stage clotting assay. The PCA of M4 extract was dependent on FVII,was not significantly affected by IA and HgCl2 and was inhibited by concanavalin A, a known TF inhibitor. An Ouchterlony double immunodiffusion study showed immunological cross-reactivity of 3LL, B16 and JWS to a polyclonal antibody to purified CP (from rabbit V2 carcinoma; obtained from S.G. Gordon, Denver, USA). No cross-reactivity was present between this antibody and M4. This study shows that the PCA of M4 is TF, whereas the procoagulant(s) of 3LL, B16 and JWS are enzymatically and immunologically indistinguishable from CP.
3
Chandra, Varkha, Sandhya Jain, Neerja Goel, Bindia Gupta, and Shalini Rajaram. "Multiple recurrence of granulosa cell tumor of the ovary: A case report and literature review." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685319.
Full textAbstract:
Introduction: Granulosa cell tumors comprise approximately 5% of all ovarian malignancy and account for 70% of malignant sex cord stromal tumors. Granulosa cell tumors have been diagnosed from infancy, the peak incidence being perimenopausal age. The potential of malignancy of these tumors is low, recurrences are often late and found in 10-33% of cases. Case Report: A 32-year-old P1L1 presented with large abdominal mass for which she underwent staging laparotomy with debulking surgery. She was a known case of granulosa cell tumor in the past and had undergone three laparotomies, along with chemotherapy. At the age of 13 yrs, she was diagnosed with a stage IA granulosa cell tumor (GCT) of the ovary first time. She underwent surgical staging and removal of left sided adnexal mass, after which she was asymptomatic for 7 years. In 2003 she again presented with lump abdomen for which she underwent resection of adnexal mass, histopathology was consistent with recurrent GCT. After second surgery she also received two cycles of chemotherapy. Despite adjuvant chemotherapy, patient presented again after three years in 2006 with adnexal mass and was found to have a third recurrence. At that time, she received 6 cycles of chemotherapy and the mass regressed. Meanwhile she got married and had one child. After four year in 2010 she again presented with lump abdomen and she underwent surgical staging, total abdominal hysterectomy with right salphingo ophorectomy along with removal of mass. After five year in 2015 she again presented with lump abdomen; there was a large pelvic mass which was removed and patient referred for chemotherapy. Discussion: GCTS which a rare malignant tumors of ovary tend to be associated with late recurrences. Although most recurrences occurs within 10 years after initial diagnosis, there are occasional reports of recurrences after10 years. We experienced the rare case of a patient who relapsed multiple times over 20 years, despite surgical and targeted treatment. Conclusion: The long history of granulosa cell tumor highlights the importance of extended follow up of the patient.
4
Chandra, Varkha, Sandhya Jain, Neerja Goel, Bindia Gupta, and Shalini Rajaram. "Multiple recurrence of granulosa cell tumor of the ovary: A case report and literature review." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685296.
Full textAbstract:
Introduction: Granulosa cell tumors comprise approximately 5% of all ovarian malignancy and account for 70% of malignant sex cord stromal tumors. Granulosa cell tumors have been diagnosed from infancy, the peak incidence being perimenopausal age. The potential of malignancy of these tumors is low, recurrences are often late and found in 10-33% of cases. Case Report: A 32-year-old P1L1 presented with large abdominal mass for which she underwent staging laparotomy with debulking surgery. She was a known case of granulosa cell tumor in the past and had undergone three laparotomies, along with chemotherapy. At the age of 13 years, she was diagnosed with a stage IA granulosa cell tumor (GCT) of the ovary first time. She underwent surgical staging and removal of left sided adnexal mass, after which she was asymptomatic for 7 years. In 2003 she again presented with lump abdomen for which she underwent resection of adnexal mass, histopathology was consistent with recurrent GCT. After second surgery she also received two cycles of chemotherapy. Despite adjuvant chemotherapy, patient presented again after three years in 2006 with adnexal mass and was found to have a third recurrence. At that time, she received 6 cycles of chemotherapy and the mass regressed. Meanwhile she got married and had one child. After four year in 2010 she again presented with lump abdomen and she underwent surgical staging, total abdominal hysterectomy with right salphingo ophorectomy along with removal of mass. After five year in 2015 she again presented with lump abdomen; there was a large pelvic mass which was removed and patient referred for chemotherapy. Discussion: GCTS which a rare malignant tumors of ovary tend to be associated with late recurrences. Although most recurrences occurs within 10 years after initial diagnosis, there are occasional reports of recurrences after10 years. We experienced the rare case of a patient who relapsed multiple times over 20 years, despite surgical and targeted treatment. In conclusion the long history of granulosa cell tumor highlights the importance of extended follow up of the patient.
5
"ASCE Manual 70 – Second Edition: Evaporation, Evapotranspiration and Irrigation Requirements." In 2015 ASABE / IA Irrigation Symposium: Emerging Technologies for Sustainable Irrigation - A Tribute to the Career of Terry Howell, Sr. Conference Proceedings. American Society of Agricultural and Biological Engineers, 2015. http://dx.doi.org/10.13031/irrig.20152143358.
Full text